Related Experiment Videos
Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants
Insights
Three pneumococcal conjugate vaccines were tested in infants. Some vaccines showed better cross-protection against related pneumococcal serotypes (6A and 19A) than others, impacting immune response assessments.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Pneumococcal conjugate vaccines (PCVs) are crucial for preventing invasive pneumococcal disease.
- PCVs target specific Streptococcus pneumoniae serotypes, but cross-protection against non-targeted serotypes is desirable.
- Evaluating the immunogenicity of PCVs, especially for cross-reactive serotypes, is essential for vaccine development.
Purpose of the Study:
- To assess the opsonophagocytic capacity and IgG antibody levels in infants immunized with experimental pneumococcal conjugate vaccines.
- To compare the cross-protective immune responses elicited by three different PCVs against Streptococcus pneumoniae serotypes 6A and 19A.
- To evaluate the correlation between opsonophagocytic activity and IgG antibody levels measured by ELISA for vaccine and cross-reactive serotypes.
Main Methods:
- Infants were immunized with one of three experimental PCVs containing serotypes 6B and 19F.
- Serum samples were analyzed for opsonophagocytic activity against Streptococcus pneumoniae serotypes 6A, 6B, 19A, and 19F.
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify IgG antibody levels against the four serotypes.
Main Results:
- All three vaccines significantly increased opsonophagocytic titers for the vaccine serotype 6B, while only two showed significant increases for the cross-reactive serotype 6A.
- Significant increases in opsonophagocytic titers were observed for serotype 19F with two vaccines and for serotype 19A with only one vaccine.
- High correlations between opsonophagocytic titers and IgG levels were found for serotypes 6B and 19F, but low correlations for serotypes 6A and 19A.
Conclusions:
- The efficacy of cross-protection against Streptococcus pneumoniae serotypes 6A and 19A varies among different pneumococcal conjugate vaccines.
- ELISA may not be a reliable surrogate marker for assessing vaccine-induced immune responses against cross-reactive serotypes.
- Further research is needed to understand and optimize the development of PCVs with broad cross-protective capabilities.
Abstract:
Infants were immunized with 1 of the 3 experimental pneumococcal conjugate vaccines that contain 6B and 19F but not 6A or 19A serotypes. Their sera were studied for the capacity to opsonize Streptococcus pneumoniae 6A, 6B, 19A, and 19F serotypes and the level of IgG antibody to the 4 serotypes. Significant increases were observed in the number of infants with detectable opsonophagocytic titers with 3 conjugate vaccines for 6B (vaccine) serotype but with only 2 vaccines for 6A (cross-reactive) serotype. Significant increases were observed with 2 conjugate vaccines for 19F serotype but with only 1 vaccine for 19A serotype. Thus, some conjugate vaccines may elicit cross-protection better than others. In addition, correlations between opsonophagocytic titers and IgG antibody levels by ELISA were high for 6B and 19F serotypes but low for 6A and 19A serotypes. Thus, ELISA may be an inadequate surrogate assay of vaccine response for cross-reactive serotypes.